COVID-19 Vaccine Policy and Regulation
COVID-19 Vaccine Policy and Regulation: A Summary for the Lay Audience
Listen to the entire interview on our Ask the Experts Podcast.
Dennis Scanlon, PhD, Distinguished Professor of Health Policy & Administration and Director, Center for Health Care & Policy Research
Will Bleser, PhD, Managing Associate, Payment Reform and Population Health at Duke-Margolis Center for Health Policy
In this episode, Dennis Scanlon speaks with Will Bleser to explore several vaccine candidates that are near ready for distribution. These vaccines, which have been proven safe and highly effective, are the results of hard work from scientists and industry and have gone through a rigorous and transparent assessment by the government and independent scientists.
Watch the full playlist of the video segments here.
Dennis Scanlon and Will Bleser talk through the regulatory process in the United States for testing the COVID-19 vaccine candidates to determine their efficacy and effectiveness. In this video they describe the research design of the clinical trials and the promising results seen thus far.
Understand more about the promising results made public from recent COVID-19 vaccine trials. In this segment our researchers also help explain what the efficacy rate actually means and how to understand these recent reports.
Take a closer look at how the Food and Drug Administration (FDA) makes the final approval for vaccine regulation in the United States. Our researchers describe how this process is conducted and how an Emergency Use Authorization can help speed up the approval for expedited distribution to the population.
Our researchers discuss the expected timeline for the COVID-19 vaccine deployment and how the Emergency Use Authorization could impact this timeline. They also discuss potential challenges faced like distribution and supply-chain issues in manufacturing doses of the vaccines.
Over the next year, the vaccines will be progressively distributed, with first priority to health care workers, critical workforce members, and the people most vulnerable to severe COVID-19, followed by the more general population.
Understand the ethical issues and other potential challenges faced in distributing a limited vaccine supply as our researchers discuss important factors to consider in achieving equitable distribution to the population both in the United States and Globally.
Our researchers explore how the rapid development of the COVID-19 vaccines will impact the development of future vaccines and other therapies.
